Autobio Diagnostics (603658) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥2.21 billion, up 4.70% year-over-year; net profit attributable to shareholders was ¥619.5 million, up 13.49% year-over-year.

• R&D investment for H1 2024 was ¥333.2 million, accounting for 15.10% of revenue; 74 new product registrations obtained.

• The company expanded its product lines in immunoassay, microbiology, biochemistry, and molecular diagnostics, with continued international market expansion.

• No interim dividend or capital increase from reserves was proposed for the period.

Financial highlights

• Operating income: ¥2.21 billion, up 4.70% year-over-year; net profit: ¥619.5 million, up 13.49% year-over-year.

• Gross margin improved, with R&D expenses rising to ¥333.2 million, up 7.18% year-over-year.

• Basic and diluted EPS: ¥1.09, up 15.96% year-over-year.

• Net cash from operating activities: ¥495.5 million, down 7.63% year-over-year.

• Total assets at period end: ¥11.04 billion; net assets attributable to shareholders: ¥8.29 billion.

Outlook and guidance

• The company will continue to focus on R&D, product innovation, and international market expansion.

• Emphasis on automation, digitalization, and comprehensive laboratory solutions to drive future growth.